







an Open Access Journal by MDPI

# Advances in Non-small Cell Lung Cancer Treatment - Current and Future

Guest Editor:

#### Dr. Azhar Ali

Cancer Science Institute Singapore, National University of Singapore, Singapore City, Singapore

Deadline for manuscript submissions:

closed (30 June 2023)

## **Message from the Guest Editor**

Dear Colleagues,

Non-small Cell Lung Cancer (NSCLC) treatments have progressed remarkably within the past decade. Mortality rates are now lower than incidence, suggesting that recent improvements in treatment strategies have significantly impacted overall survival.

As we progress towards the mid-2020s, it is fitting to commemorate the advancements in NSCLC treatment with a Special Issue of the journal *Pharmaceuticals*. We seek both reviews and original articles focusing on discovery of mutational targets (molecular testing), development of novel therapeutic strategies (immunotherapy and targeted), drug delivery and discovery. We also welcome articles covering other topics with the aim of improving or providing an alternative paradigm of NSCLC treatment.













an Open Access Journal by MDPI

## **Editor-in-Chief**

## Prof. Dr. Amélia Pilar Rauter Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

#### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

#### **Contact Us**